Table 3

Change in efficacy 2 weeks, 12 weeks and 24 weeks after the introduction of JAK inhibitors

TOFA (n=153)†BARI (n=141)†
Change from baselineChange from baseline
Week 2Week 12Week 24Week 2Week 12Week 24
CDAI−12.3 (11.2)*−17.2 (12.6)*−18.1 (13.0)*−11.5 (11.6)*−18.3 (13.0)*−19.3 (14.1)*
SDAI−12.5 (11.6)*−17.9 (13.5)*−19.0 (14.1)*−12.3 (12.5)*−19.1 (13.8)*−20.4 (15.0)*
HAQ-DI−0.22 (0.41)*−0.41 (0.53)*−0.45 (0.61)*−0.15 (0.38)*−0.31 (0.55)*−0.39 (0.65)*
CRP, mg/dL−0.06 (-0.92–0.00)*−0.05 (–1.30–0.02)*−0.11 (–1.30–0.00)*−0.07 (–0.70–0.00)*−0.05 (–1.11–0.00)*−0.13 (–1.55–0.02)*
ESR, mm/hour−5.46 (14.21)*−7.66 (21.9)*−10.78 (26.7)*−6.48 (14.66)*−10.23 (22.77)*−12.84 (33.39)*
  • Change from baseline data is mean (SD) and median (IQR).

  • *P≤0.001 from within-group mean change from baseline.

  • †The number of subjects changed after IPTW in the calculation; however, the actual number of subjects did not change.

  • BARI, baricitinib; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; JAK, Janus kinase; SDAI, Simplified Disease Activity Index; TOFA, tofacitinib.